Some studies have identified bisphosphonate use as a risk factor for atrial fibrillation (AF), though meta-analysis of them finds conflicting reports. , the US Food and Drug Administration did not recommend any alteration in prescribing of bisphosphonates based on AF concerns. More recent meta-analyses have found strong correlations between bisphosphonate use and development of AF, especially when administered intravenously, but that a significantly increased risk of AF that required hospitalization did not have an attendant increased risk of stroke or cardiovascular mortality.